These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

680 related items for PubMed ID: 17062609

  • 1. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
    Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F.
    J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609
    [Abstract] [Full Text] [Related]

  • 2. Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin.
    Brinch KS, Tulkens PM, Van Bambeke F, Frimodt-Møller N, Høiby N, Kristensen HH.
    J Antimicrob Chemother; 2010 Aug; 65(8):1720-4. PubMed ID: 20534628
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG, Voth D, Nichol K, Karlowsky JA, Noreddin AM, Hoban DJ.
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [Abstract] [Full Text] [Related]

  • 4. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.
    Baudoux P, Lemaire S, Denis O, Tulkens PM, Van Bambeke F, Glupczynski Y.
    J Antimicrob Chemother; 2010 Jun; 65(6):1228-36. PubMed ID: 20378672
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG, Basuino L, Chambers HF.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [Abstract] [Full Text] [Related]

  • 6. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
    Leuthner KD, Cheung CM, Rybak MJ.
    J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
    [Abstract] [Full Text] [Related]

  • 7. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).
    Leonard SN, Szeto YG, Zolotarev M, Grigoryan IV.
    Int J Antimicrob Agents; 2011 Jun; 37(6):558-61. PubMed ID: 21497067
    [Abstract] [Full Text] [Related]

  • 8. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F, Aguilar L, González N, Giménez MJ, Torrico M, Alou L, Sevillano D, Vallejo P, Prieto J.
    J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
    [Abstract] [Full Text] [Related]

  • 9. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus.
    Saravolatz LD, Pawlak J, Johnson LB.
    J Antimicrob Chemother; 2007 Aug; 60(2):406-9. PubMed ID: 17586562
    [Abstract] [Full Text] [Related]

  • 10. Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
    Lubenko IY, Strukova EV, Smirnova MV, Vostrov SN, Portnoy YA, Zinner SH, Firsov AA.
    J Antimicrob Chemother; 2008 Nov; 62(5):1065-9. PubMed ID: 18635520
    [Abstract] [Full Text] [Related]

  • 11. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
    Hegde SS, Skinner R, Lewis SR, Krause KM, Blais J, Benton BM.
    J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model.
    Hegde SS, Difuntorum S, Skinner R, Trumbull J, Krause KM.
    J Antimicrob Chemother; 2009 Apr; 63(4):763-6. PubMed ID: 19155225
    [Abstract] [Full Text] [Related]

  • 13. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage.
    Alós JI, García-Cañas A, García-Hierro P, Rodríguez-Salvanés F.
    J Antimicrob Chemother; 2008 Oct; 62(4):773-5. PubMed ID: 18552338
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis.
    Lemaire S, Kosowska-Shick K, Julian K, Tulkens PM, Van Bambeke F, Appelbaum PC.
    Clin Microbiol Infect; 2008 Aug; 14(8):766-77. PubMed ID: 18727801
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus.
    Reyes N, Skinner R, Benton BM, Krause KM, Shelton J, Obedencio GP, Hegde SS.
    J Antimicrob Chemother; 2006 Aug; 58(2):462-5. PubMed ID: 16735425
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus.
    Hegde SS, Reyes N, Skinner R, Difuntorum S.
    J Antimicrob Chemother; 2008 Jan; 61(1):169-72. PubMed ID: 17993505
    [Abstract] [Full Text] [Related]

  • 20. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA, Beaulieu S, Arhin FF, Belley A, Sarmiento I, Parr T, Moeck G.
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.